{"title":"IVIG in Immunocompromised Pediatric Patients - Advances and Prospects?","authors":"K. Derwich","doi":"10.26420/annhematoloncol.2018.1224","DOIUrl":null,"url":null,"abstract":"Continuous development of effective antineoplastic therapies causes that immunodeficiencies are estimated to be one of the most vital problem of treatment. One of the possible keys for that could be Intravenous Immunoglobulins (IVIGs), but recommendations about substitution are not straightforward. if 4-5g/L is introduce a of pediatric patients with lack of unequivocal guidelines both should orientated in a role of on therapies and prevention for pediatric hemato-oncology","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hematology & oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26420/annhematoloncol.2018.1224","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Continuous development of effective antineoplastic therapies causes that immunodeficiencies are estimated to be one of the most vital problem of treatment. One of the possible keys for that could be Intravenous Immunoglobulins (IVIGs), but recommendations about substitution are not straightforward. if 4-5g/L is introduce a of pediatric patients with lack of unequivocal guidelines both should orientated in a role of on therapies and prevention for pediatric hemato-oncology
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
